DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
TYK2 as a Biomarker and Therapeutic Target for NF1-Associated Malignant Peripheral Nerve Sheath Tumors
[Technical Report, Annual Report]
WASHINGTON UNIV ST LOUIS MO
Pagination or Media Count:
Malignant peripheral nerve sheath tumors MPNST are aggressive sarcomas that account for 5 of all soft tissue sarcomas. These tumors occur at an increased frequency in patients with the Neurofibromatosis Type 1 NF1 cancer predisposition syndrome, but also occur sporadically or secondary to radiation therapy. In the setting of NF1, MPNST arise from malignant transformation of a benign precursor lesion, a plexiform neurofibroma. Despite aggressive therapy, the recurrence rate is high and the vast majority of people with these cancers will die within 5 years of diagnosis. Given limited treatment options, there is a pressing need to identify novel therapeutic targets. Our laboratory previously identified TYK2 as a gene mutated in a subset of MPNSTs. More recently, we have shown that genetic knockdown of TYK2 in both human and murine MPNST cell lines results in increased cell death in vitro and decreased tumor growth.
[A, Approved For Public Release]